Syros Therapy SY-1425 Wins FDA’s Orphan Drug Designation to Treat Acute Myeloid Leukemia
News
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SY-1425 to treat acute myeloid leukemia (AML), said the drug’s developer, Syros Pharmaceuticals. The therapy is being tested ... Read more